FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2158082603> ?p ?o ?g. }

• W2158082603 endingPage "401" @default.
• W2158082603 startingPage "401" @default.
• W2158082603 abstract "Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence Maxine Sun,1 Alessandro Larcher,1,2 Pierre I Karakiewicz1 1Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada; 2Department of Urology, Università Vita-Salute San Raffaele, Milan, Italy Abstract: Since 2005, an abundance of targeted agents has been approved for the treatment of metastatic renal cell carcinoma (mRCC), without any specification as to what may be the most optimal first-line and second-line sequence. Hence, our objective was to critically examine the evidence supporting the use of first-line and second-line agents in the management of mRCC. Our review suggests that in first line, sunitinib and pazopanib represent treatment options for patients with favorable or intermediate-risk features and clear cell histology. Unfortunately, the Phase III trial cannot conclusively prove the noninferiority of pazopanib relative to sunitinib. Hence, the use of sunitinib as first-line standard of care remains justified. Pazopanib represents an option for specific patients in whom sunitinib might not be tolerated. In patients with poor-risk features, temsirolimus represents the only option supported with level 1 evidence. Less optimal alternatives include sunitinib and bevacizumab combined with interferon, based on the minimal inclusion of poor-risk patients in pivotal Phase III studies of these two molecules. In patients with non-clear cell mRCC, the use of temsirolimus is supported by Phase III data, unlike for any other molecule. In second line, the options consist of everolimus and axitinib. However, the axitinib data are substantially more robust given the inclusion of more patients considered as true second-line, and validly justify the choice of axitinib over everolimus. Nonetheless, the Phase III trial of everolimus may be considered as level 1 evidence for use as third-line or subsequent lines of therapy. Keywords: targeted therapy, metastatic, renal cell carcinoma, clear cell, sequential therapy" @default.
• W2158082603 created "2016-06-24" @default.
• W2158082603 creator A5022182189 @default.
• W2158082603 creator A5044228660 @default.
• W2158082603 creator A5060378122 @default.
• W2158082603 date "2014-10-01" @default.
• W2158082603 modified "2023-09-27" @default.
• W2158082603 title "Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence" @default.
• W2158082603 cites W1520255941 @default.
• W2158082603 cites W1522152077 @default.
• W2158082603 cites W196236547 @default.
• W2158082603 cites W1999966467 @default.
• W2158082603 cites W2023952988 @default.
• W2158082603 cites W2034202045 @default.
• W2158082603 cites W2074416418 @default.
• W2158082603 cites W2078449820 @default.
• W2158082603 cites W2099088585 @default.
• W2158082603 cites W2099752220 @default.
• W2158082603 cites W2100669312 @default.
• W2158082603 cites W2110720470 @default.
• W2158082603 cites W2115005218 @default.
• W2158082603 cites W2118677643 @default.
• W2158082603 cites W2122132792 @default.
• W2158082603 cites W2136110110 @default.
• W2158082603 cites W2138129102 @default.
• W2158082603 cites W2141444851 @default.
• W2158082603 cites W2143782771 @default.
• W2158082603 cites W2149456801 @default.
• W2158082603 cites W2152740900 @default.
• W2158082603 cites W2153867442 @default.
• W2158082603 cites W2155012968 @default.
• W2158082603 cites W2157262448 @default.
• W2158082603 cites W2160476851 @default.
• W2158082603 cites W2162424705 @default.
• W2158082603 cites W4248217871 @default.
• W2158082603 cites W4253292111 @default.
• W2158082603 doi "https://doi.org/10.2147/ijnrd.s48496" @default.
• W2158082603 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4219683" @default.
• W2158082603 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25378943" @default.
• W2158082603 hasPublicationYear "2014" @default.
• W2158082603 type Work @default.
• W2158082603 sameAs 2158082603 @default.
• W2158082603 citedByCount "15" @default.
• W2158082603 countsByYear W21580826032015 @default.
• W2158082603 countsByYear W21580826032016 @default.
• W2158082603 countsByYear W21580826032017 @default.
• W2158082603 countsByYear W21580826032018 @default.
• W2158082603 countsByYear W21580826032019 @default.
• W2158082603 countsByYear W21580826032020 @default.
• W2158082603 crossrefType "journal-article" @default.
• W2158082603 hasAuthorship W2158082603A5022182189 @default.
• W2158082603 hasAuthorship W2158082603A5044228660 @default.
• W2158082603 hasAuthorship W2158082603A5060378122 @default.
• W2158082603 hasBestOaLocation W21580826031 @default.
• W2158082603 hasConcept C126322002 @default.
• W2158082603 hasConcept C143998085 @default.
• W2158082603 hasConcept C183713625 @default.
• W2158082603 hasConcept C185592680 @default.
• W2158082603 hasConcept C190283241 @default.
• W2158082603 hasConcept C2776539811 @default.
• W2158082603 hasConcept C2776694085 @default.
• W2158082603 hasConcept C2776820818 @default.
• W2158082603 hasConcept C2777472916 @default.
• W2158082603 hasConcept C2777802072 @default.
• W2158082603 hasConcept C2778439243 @default.
• W2158082603 hasConcept C2779490328 @default.
• W2158082603 hasConcept C2779699572 @default.
• W2158082603 hasConcept C55493867 @default.
• W2158082603 hasConcept C71924100 @default.
• W2158082603 hasConcept C86554907 @default.
• W2158082603 hasConceptScore W2158082603C126322002 @default.
• W2158082603 hasConceptScore W2158082603C143998085 @default.
• W2158082603 hasConceptScore W2158082603C183713625 @default.
• W2158082603 hasConceptScore W2158082603C185592680 @default.
• W2158082603 hasConceptScore W2158082603C190283241 @default.
• W2158082603 hasConceptScore W2158082603C2776539811 @default.
• W2158082603 hasConceptScore W2158082603C2776694085 @default.
• W2158082603 hasConceptScore W2158082603C2776820818 @default.
• W2158082603 hasConceptScore W2158082603C2777472916 @default.
• W2158082603 hasConceptScore W2158082603C2777802072 @default.
• W2158082603 hasConceptScore W2158082603C2778439243 @default.
• W2158082603 hasConceptScore W2158082603C2779490328 @default.
• W2158082603 hasConceptScore W2158082603C2779699572 @default.
• W2158082603 hasConceptScore W2158082603C55493867 @default.
• W2158082603 hasConceptScore W2158082603C71924100 @default.
• W2158082603 hasConceptScore W2158082603C86554907 @default.
• W2158082603 hasLocation W21580826031 @default.
• W2158082603 hasLocation W21580826032 @default.
• W2158082603 hasLocation W21580826033 @default.
• W2158082603 hasLocation W21580826034 @default.
• W2158082603 hasOpenAccess W2158082603 @default.
• W2158082603 hasPrimaryLocation W21580826031 @default.
• W2158082603 hasRelatedWork W1973011217 @default.
• W2158082603 hasRelatedWork W1984657347 @default.
• W2158082603 hasRelatedWork W2076823089 @default.
• W2158082603 hasRelatedWork W2146882722 @default.
• W2158082603 hasRelatedWork W2154171266 @default.
• W2158082603 hasRelatedWork W2385876243 @default.

• next